SB 18-023

Senate Bill 18-023, which has been signed into law, allows pharmaceutical companies and their representatives to promote the off-label use of prescription drugs, biological products, or devices that have already been approved by the U.S. Food and Drug Administration (FDA). This means they can discuss uses for these medications beyond what is officially approved by the FDA with healthcare providers and patients. The bill affects pharmaceutical manufacturers and healthcare professionals who prescribe medication. Since it has been signed, the law is now in effect and changes how off-label promotion of drugs can be conducted in Colorado.

Official Summary

The bill allows a pharmaceutical manufacturer or its representative to promote the off-label use of a prescription drug, biological product, or device approved by the United States food and drug administration. (Note: This summary applies to this bill as introduced.) , Read More